Warum Bitcoin als Wertspeicher in keinem diversifizierten Portfolio fehlen sollte. Jetzt lesen -w-
18.10.2017 23:43:00

Global Down Syndrome Foundation Thanks Congressional Leaders for Scheduling Hearing on the Importance of Down Syndrome Research and its Potential for Discoveries Across Major Diseases

WASHINGTON, Oct. 18, 2017 /PRNewswire/ -- The Global Down Syndrome Foundation thanked Chairman Tom Cole (R-OK) and Ranking Member Rosa DeLauro (D-CT) for scheduling a hearing on Down syndrome research with the U.S. House of Representatives Appropriations Subcommittee on Labor, Health and Human Services, and Education. The hearing will take place on Wednesday, October 25, 2017. Titled "Down Syndrome: Update on the State of the Science & Potential for Discoveries Across Other Major Diseases," the hearing will be the first Congressional hearing to explore how Down syndrome research can lead to new treatments for life-altering medical conditions including Alzheimer's disease, autoimmune disorders, and cancer. The hearing will include testimony from Rep. Cathy McMorris Rodgers (R-WA),  Rep. Cheri Bustos (D-IL), and Rep. Pete Sessions (R-TX), all champions for Down syndrome research funding in Congress.

"Funding for Down syndrome research at the National Institutes of Health unquestionably affects the health of people with Down syndrome," said Global Down Syndrome Foundation President & CEO Michelle Sie Whitten. "This important hearing will explore how current and future Down syndrome research can help people with Down syndrome and lead to life-changing treatments for devastating diseases like Alzheimer's and cancer. We are grateful to Chairman Tom Cole and Ranking Member Rosa DeLauro for scheduling this important hearing so Congress can learn more about the broad impact of Down syndrome research for millions of people who live with this particular condition, and for countless others who can benefit from the groundbreaking medical treatments that will develop as a result."

"The advocacy efforts of Rep. Cathy McMorris Rodgers, Rep. Cheri Bustos, and Rep. Pete Sessions have been instrumental in advancing Down syndrome research," Whitten continued. "Their testimony will underscore the need to increase funding so we can continue these important efforts for people with Down syndrome and their families."

The Subcommittee will also hear testimony from internationally recognized researchers and leaders from the Down syndrome community including:

Michelle Sie Whitten, Founder, CEO, and President of the Global Down Syndrome Foundation

Dr. Joaquín M. Espinosa, Executive Director of the Linda Crnic Institute for Down Syndrome and Director of The Functional Genomics Facility, University of Colorado School of Medicine, and Co-Leader of the Molecular Oncology Program at the University of Colorado Cancer Center

Dr. William Mobley, Executive Director of the Down Syndrome Center for Research and Treatment, and Florence Riford Chair of Alzheimer's Disease Research, University of California - San Diego

Frank Stephens
Actor, Author and Advocate, Board of Directors of Special Olympics Virginia

Additional information can be found on the House Committee on Appropriation web site.

Read more about the Global Down Syndrome Foundation here: https://www.globaldownsyndrome.org/

Media Contact
Name: Ed Mullen
Email: emullen@georgetowngroup.com
Phone: (202) 329-4855

Anca Call
Email: Acall@globaldownsyndrome.org
Phone: (720) 320-3832

Kathy Green
Email: kgreen@globaldownsyndrome.org

Follow on Twitter at: https://twitter.com/GDSFoundation
Follow on Facebook at: https://www.facebook.com/GDSFoundation/

SOURCE Global Down Syndrome Foundation

Related Links

https://www.globaldownsyndrome.org/ 

https://appropriations.house.gov/calendar/eventsingle.aspx?EventID=395058

View original content with multimedia:http://www.prnewswire.com/news-releases/global-down-syndrome-foundation-thanks-congressional-leaders-for-scheduling-hearing-on-the-importance-of-down-syndrome-research-and-its-potential-for-discoveries-across-major-diseases-300539410.html

SOURCE Global Down Syndrome Foundation

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!